Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride (KCl) replaces potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.
Treatment or prevention of hypokalemia,Maintenance of potassium levels in patients with normal renal function,Correction of potassium deficiency in patients on diuretics or with gastrointestinal losses,Off-label: Prevention of hypokalemia in patients receiving digitalis
Treatment or prevention of hypokalemia,Correction of potassium deficiency,Parenteral nutrition,Maintenance of electrolyte balance in patients unable to take oral fluids
10-20 m Eq potassium chloride IV infused at a rate not exceeding 10-20 m Eq/hour; maximum 40 m Eq per dose. Administer in dextrose 5% solution.
10-20 m Eq/hour intravenously, not to exceed 20 m Eq/hour; maximum 200 m Eq/day; adjust based on serum potassium levels.
Potassium has no classic elimination half-life; distribution and excretion are rapid with a plasma half-life of approximately 1–1.5 hours in healthy individuals, but this is clinically irrelevant as body stores are regulated by renal function.
Terminal half-life approximately 0.5-1 hour for rapid distribution; clinical context: potassium is primarily intracellular, and serum half-life reflects redistribution rather than elimination. In renal impairment, half-life may prolong due to decreased excretion.
Potassium is primarily excreted unchanged by the kidneys (90%) with minor fecal loss. Dextrose is metabolized via glycolysis and oxidative phosphorylation.
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle.
Renal: >90% of potassium is excreted renally, primarily via distal tubular secretion; a small fraction is lost in feces (<10%) and negligible biliary elimination.
Renal: >90% as potassium ions; feces: <10%; negligible biliary excretion.
Not significantly protein-bound; <1% bound to plasma proteins.
Minimal; approximately 0-10% bound to albumin; most potassium is free in plasma.
Approximately 0.5–0.7 L/kg; reflects distribution primarily into extracellular fluid (15% of body weight) and rapid equilibration with intracellular stores, though Vd is not well-defined for potassium due to active transport.
Approximately 0.5-0.7 L/kg (total body water distribution); clinical meaning: potassium distributes primarily into intracellular space (98%), with Vd reflecting total body water. Higher Vd indicates larger intracellular stores.
Intravenous: 100% bioavailable. Oral: 80–90% bioavailable (absorption from gastrointestinal tract is nearly complete, but first-pass uptake by the liver is minimal).
Oral: 85-100% (well absorbed); Intravenous: 100%.
GFR 30-50 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or use with extreme caution, reduce dose by 50-75% and monitor serum potassium closely.
GFR 30-50 m L/min: administer with caution, maximum 100 m Eq/day. GFR <30 m L/min: avoid use or reduce dose to 50% of standard; monitor potassium closely.
No specific dose adjustment recommended; monitor potassium levels due to potential risk of hyperkalemia in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose to 50-75% of standard, but evidence limited; monitor potassium levels.
0.5-1 m Eq/kg per dose IV, infused at a rate of 0.5 m Eq/kg/hour; maximum 1 m Eq/kg per dose up to 40 m Eq total.
IV: 0.5-1 m Eq/kg/dose, up to 20 m Eq/dose, infused at 0.3-0.5 m Eq/kg/hour; maximum 1 m Eq/kg/hour. Adjust based on deficiency and monitoring.
Start with lower end of dosing range (10-20 m Eq); maximum infusion rate 10 m Eq/hour; monitor renal function and serum potassium frequently.
Initiate at low end of dosing range (5-10 m Eq/hour IV); maximum 100 m Eq/day; monitor renal function and potassium levels frequently due to age-related decline.
Potassium chloride injection concentrate must be diluted before use. Rapid infusion may cause fatal hyperkalemia and cardiac arrest. Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia.
Concentrated potassium chloride solutions (≥2 m Eq/m L) must be diluted before administration. Rapid intravenous administration of undiluted potassium chloride can cause fatal hyperkalemia and cardiac arrest.
Hyperkalemia risk: Monitor serum potassium levels, especially in renal impairment.,Cardiac effects: ECG changes may occur with hyperkalemia; avoid rapid infusion.,Extravasation: Can cause tissue necrosis; ensure proper IV access.,Dextrose content: May cause hyperglycemia; caution in diabetes mellitus.,Administration: Do not administer undiluted; use with infusion pump for concentrated solutions.
Monitor serum potassium, glucose, and electrolyte levels frequently,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Adjust rate of infusion based on clinical status and laboratory values,Avoid extravasation as may cause tissue necrosis
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal impairment with oliguria or anuria,Acute dehydration or heat cramps,Adrenal insufficiency (Addison's disease),Concurrent use with potassium-sparing diuretics,Patients with hyperchloremia (for KCl only)
Hyperkalemia,Severe renal impairment with oliguria or anuria,Concurrent use with potassium-sparing diuretics or ACE inhibitors (relative),Adams-Stokes syndrome,Severe hemolytic reactions
Avoid high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes) unless directed by your healthcare provider. Maintain consistent dietary potassium intake while on therapy.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits) to reduce risk of hyperkalemia. No known direct food-drug interactions with potassium chloride, but dietary potassium should be monitored.
Pregnancy Category C. Potassium chloride is an electrolyte; no teratogenic effects reported in humans. Risk of fetal hyperkalemia if maternal hyperkalemia occurs. First trimester: no human data; animal studies not conducted. Second/third trimesters: increased risk of cardiac arrhythmias in fetus if maternal potassium levels are abnormal.
Potassium chloride is a physiologic electrolyte. No teratogenic effects are expected. There is no evidence of fetal risk at therapeutic doses; however, maternal hyperkalemia may cause fetal arrhythmias. In first trimester, no known structural teratogenicity. In second and third trimesters, maternal potassium imbalance can affect fetal cardiac conduction.
Potassium is normally present in breast milk. Exogenous administration is unlikely to affect breastfeeding infant significantly. M/P ratio not established; potassium is a normal milk constituent. Use with caution if maternal hyperkalemia present.
Potassium chloride is endogenous and excreted into breast milk in small amounts. The M/P ratio is approximately 0.9. At maternal therapeutic doses, no adverse effects in breastfed infants are anticipated. Use is considered compatible with breastfeeding.
Pregnancy may alter potassium requirements due to increased plasma volume and renal function. Dose adjustments should be guided by serum potassium levels, not fixed changes. Hypokalemia may require higher doses; avoid hyperkalemia.
Pregnancy does not significantly alter potassium pharmacokinetics. No routine dose adjustment is recommended. However, plasma volume expansion in pregnancy may dilute potassium; monitor serum levels. Consider increased renal excretion; adjust dose based on serum potassium and clinical status.
Potassium chloride in dextrose 5% is indicated for hypokalemia with fluid/caloric needs. Administer via central line if concentration > 60 m Eq/L; peripheral infusion requires concentration ≤ 60 m Eq/L and rate ≤ 10 m Eq/hr. Never give IV bolus; max infusion rate 20 m Eq/hr with ECG monitoring. Contraindicated in hyperkalemia, severe renal impairment, and conditions with tissue breakdown. Monitor serum potassium, renal function, and ECG during infusion.
Potassium chloride 20 m Eq in D5W is typically administered at a rate not exceeding 10 m Eq/hour via peripheral line to avoid phlebitis; central line administration allows rates up to 20 m Eq/hour with cardiac monitoring. Do not administer undiluted or via IV push due to risk of fatal hyperkalemia. Use with caution in patients with renal impairment, heart block, or digitalis toxicity. Incompatible with amiodarone, diazepam, and phenytoin. Monitor serum potassium and ECG during infusion. Correct hypomagnesemia before potassium repletion to prevent refractory hypokalemia.
This medication is used to treat low potassium levels and provide calories and fluids.,You may experience burning or pain at the IV site; report immediately.,Do not adjust the infusion rate yourself.,Inform your doctor if you have kidney problems, heart conditions, or take potassium-sparing diuretics.,Report symptoms of high potassium: muscle weakness, numbness, tingling, irregular heartbeat.
This medication is used to treat or prevent low potassium levels in your blood.,You will receive this medication through a vein (IV) in a hospital setting.,Inform your healthcare provider if you have kidney problems, heart disease, or are taking any other medications, especially diuretics or digoxin.,Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling in the hands or feet.,Do not eat large amounts of potassium-rich foods (e.g., bananas, oranges, potatoes) without consulting your doctor.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Replenisher that works by Potassium chloride (KCl) replaces potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.. POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Replenisher that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER and POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Replenisher agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is: 10-20 m Eq potassium chloride IV infused at a rate not exceeding 10-20 m Eq/hour; maximum 40 m Eq per dose. Administer in dextrose 5% solution.. The standard adult dose of POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is: 10-20 m Eq/hour intravenously, not to exceed 20 m Eq/hour; maximum 200 m Eq/day; adjust based on serum potassium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER and POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category C. Potassium chloride is an electrolyte; no teratogenic effects reported in humans. Risk of fetal hyperkalemia if maternal hyperkalemia occurs. First trimester: . POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride is a physiologic electrolyte. No teratogenic effects are expected. There is no evidence of fetal risk at therapeutic doses; however, maternal hyperkalemia may ca. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.